American journal of veterinary research · 2025
Prophylactic use of canine parvovirus monoclonal antibody induces blockade of vaccinal canine parvovirus immunization similar to maternally derived passive immunity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Larson Laurie, Hansen Jason, Ramasami Prakash, Miller Jennifer M, Slagter Barton J, Tremblay Danielle, Patel Mayur, Wasmoen Terri
Аннотация
OBJECTIVE: To determine initial antibody titer, degradation profile, and duration of passive antibody blockade of active immunization by modified-live viral (MLV) canine parvovirus (CPV-2) vaccine following CPV monoclonal antibody (CPMA) prophylactic subcutaneous (SC) administration to CPV-2-naïve puppies.
METHODS: Purpose-bred, CPV-2-seronegative male and female Beagle dogs, 7 to 8 weeks of age, were randomized to CPMA treatment (n = 13) and control (7) groups. Dogs were commingled and group housed in a shower-in/shower-out facility. At study day 0, dogs were administered either 0.1 mL/kg body weight CPMA SC or an equivalent volume of saline. Sera collected weekly over 140 days were assayed via hemagglutination inhibition and serum virus neutralization. All dogs were administered a commercially available MLV vaccine containing CPV-2 in combination with other core vaccine viruses at 3-week time points beginning at study day 42.
RESULTS: All control dogs remained seronegative through day 42 and seroconverted to CPV-2 after the initial dose of MLV vaccine. By study day 1, the CPMA-treated group showed a mean passive hemagglutination inhibition titer of 1,674. The average degradation rate was calculated at R2 = 0.97, with a mean half-life of 18.9 days. Twelve of 13 (92%) in the treated group seroconverted after a fourth vaccination on day 105.
CONCLUSIONS: Prophylactic CPMA at 0.1 mL/kg body weight SC can block active CPV-2 immunization for 15 weeks when given to seronegative puppies.
CLINICAL RELEVANCE: Initial puppy vaccination series should be extended after CPMA prophylactic use.
METHODS: Purpose-bred, CPV-2-seronegative male and female Beagle dogs, 7 to 8 weeks of age, were randomized to CPMA treatment (n = 13) and control (7) groups. Dogs were commingled and group housed in a shower-in/shower-out facility. At study day 0, dogs were administered either 0.1 mL/kg body weight CPMA SC or an equivalent volume of saline. Sera collected weekly over 140 days were assayed via hemagglutination inhibition and serum virus neutralization. All dogs were administered a commercially available MLV vaccine containing CPV-2 in combination with other core vaccine viruses at 3-week time points beginning at study day 42.
RESULTS: All control dogs remained seronegative through day 42 and seroconverted to CPV-2 after the initial dose of MLV vaccine. By study day 1, the CPMA-treated group showed a mean passive hemagglutination inhibition titer of 1,674. The average degradation rate was calculated at R2 = 0.97, with a mean half-life of 18.9 days. Twelve of 13 (92%) in the treated group seroconverted after a fourth vaccination on day 105.
CONCLUSIONS: Prophylactic CPMA at 0.1 mL/kg body weight SC can block active CPV-2 immunization for 15 weeks when given to seronegative puppies.
CLINICAL RELEVANCE: Initial puppy vaccination series should be extended after CPMA prophylactic use.